SpringWorks Net Invested Capital vs Capital Surpluse Analysis

SWTX Stock

USD 45.11 1.76 4.06%

SpringWorks Therapeutics financial indicator trend analysis is much more than just breaking down SpringWorks Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether SpringWorks Therapeutics is a good investment. Please check the relationship between SpringWorks Therapeutics Net Invested Capital and its Capital Surpluse accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in SpringWorks Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy SpringWorks Stock please use our How to Invest in SpringWorks Therapeutics guide.

Net Invested Capital vs Capital Surpluse

Net Invested Capital vs Capital Surpluse Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of SpringWorks Therapeutics Net Invested Capital account and Capital Surpluse. At this time, the significance of the direction appears to have almost identical trend.

The correlation between SpringWorks Therapeutics' Net Invested Capital and Capital Surpluse is 0.96. Overlapping area represents the amount of variation of Net Invested Capital that can explain the historical movement of Capital Surpluse in the same time period over historical financial statements of SpringWorks Therapeutics, assuming nothing else is changed. The correlation between historical values of SpringWorks Therapeutics' Net Invested Capital and Capital Surpluse is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Invested Capital of SpringWorks Therapeutics are associated (or correlated) with its Capital Surpluse. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capital Surpluse has no effect on the direction of Net Invested Capital i.e., SpringWorks Therapeutics' Net Invested Capital and Capital Surpluse go up and down completely randomly.

Correlation Coefficient

0.96

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Net Invested Capital

The total amount of capital invested in a company, including both equity and debt, minus any cash or cash equivalents.

Capital Surpluse

Most indicators from SpringWorks Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into SpringWorks Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in SpringWorks Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy SpringWorks Stock please use our How to Invest in SpringWorks Therapeutics guide.At this time, SpringWorks Therapeutics' Selling General Administrative is fairly stable compared to the past year. Sales General And Administrative To Revenue is likely to rise to 38.08 in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 237.1 M in 2024.

	2021	2022	2023	2024 (projected)
Cost Of Revenue	490K	1.9M	422K	400.9K
Research Development	101.7M	146.1M	150.5M	158.0M

Cost Of Revenue Research Development

SpringWorks Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Accounts Payable	Cash	Other Assets	Short Term Investments	Inventory	Other Current Assets	Total Liab	Treasury Stock	Intangible Assets	Common Stock	Property Plant Equipment	Long Term Debt	Preferred Stock Total Equity	Good Will	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments
Total Assets		0.91	0.8	0.53	0.82	0.43	0.7	0.84	0.12	0.19	0.94	0.69	0.64	0.31	0.65	0.28	-0.19	-0.64	-0.64	0.94	0.86	-0.68	-0.89	0.82	0.94	0.95
Other Current Liab	0.91		0.9	0.51	0.92	0.51	0.54	0.75	0.02	0.34	0.97	0.85	0.83	0.31	0.79	0.37	-0.14	-0.84	-0.84	0.77	0.98	-0.52	-0.99	0.94	0.84	0.76
Total Current Liabilities	0.8	0.9		0.41	0.8	0.83	0.42	0.81	-0.34	0.69	0.86	0.89	0.73	-0.13	0.87	0.73	0.3	-0.74	-0.74	0.64	0.86	-0.41	-0.87	0.82	0.7	0.63
Total Stockholder Equity	0.53	0.51	0.41		0.33	0.09	0.63	0.36	-0.31	0.22	0.59	0.28	0.6	0.25	0.45	0.0	-0.13	-0.6	-0.6	0.45	0.35	-0.63	-0.43	0.72	0.48	0.37
Other Liab	0.82	0.92	0.8	0.33		0.43	0.39	0.76	0.09	0.2	0.93	0.76	0.68	0.34	0.66	0.28	-0.21	-0.69	-0.69	0.71	0.9	-0.37	-0.94	0.82	0.82	0.71
Accounts Payable	0.43	0.51	0.83	0.09	0.43		0.16	0.66	-0.64	0.9	0.48	0.67	0.34	-0.65	0.68	0.98	0.76	-0.34	-0.34	0.32	0.47	-0.17	-0.46	0.37	0.34	0.33
Cash	0.7	0.54	0.42	0.63	0.39	0.16		0.46	0.09	0.02	0.62	0.31	0.42	0.31	0.33	0.0	-0.24	-0.43	-0.43	0.69	0.45	-1.0	-0.5	0.52	0.66	0.69
Other Assets	0.84	0.75	0.81	0.36	0.76	0.66	0.46		-0.2	0.38	0.83	0.63	0.52	-0.1	0.48	0.56	0.18	-0.33	-0.33	0.87	0.68	-0.45	-0.73	0.62	0.88	0.84
Short Term Investments	0.12	0.02	-0.34	-0.31	0.09	-0.64	0.09	-0.2		-0.84	-0.03	-0.17	-0.1	0.79	-0.33	-0.7	-0.85	0.08	0.08	0.19	0.15	-0.06	-0.11	-0.07	0.15	0.26
Inventory	0.19	0.34	0.69	0.22	0.2	0.9	0.02	0.38	-0.84		0.29	0.55	0.34	-0.72	0.69	0.92	0.84	-0.4	-0.4	0.02	0.28	-0.03	-0.27	0.33	0.05	0.0
Other Current Assets	0.94	0.97	0.86	0.59	0.93	0.48	0.62	0.83	-0.03	0.29		0.78	0.75	0.29	0.73	0.33	-0.15	-0.75	-0.75	0.84	0.9	-0.61	-0.94	0.91	0.91	0.82
Total Liab	0.69	0.85	0.89	0.28	0.76	0.67	0.31	0.63	-0.17	0.55	0.78		0.73	0.01	0.79	0.58	0.15	-0.74	-0.74	0.5	0.85	-0.3	-0.84	0.77	0.64	0.52
Treasury Stock	0.64	0.83	0.73	0.6	0.68	0.34	0.42	0.52	-0.1	0.34	0.75	0.73		0.31	0.59	0.25	-0.15	-0.8	-0.8	0.53	0.82	-0.4	-0.84	0.91	0.61	0.44
Intangible Assets	0.31	0.31	-0.13	0.25	0.34	-0.65	0.31	-0.1	0.79	-0.72	0.29	0.01	0.31		-0.07	-0.76	-0.98	-0.34	-0.34	0.3	0.35	-0.28	-0.36	0.37	0.34	0.3
Common Stock	0.65	0.79	0.87	0.45	0.66	0.68	0.33	0.48	-0.33	0.69	0.73	0.79	0.59	-0.07		0.6	0.25	-0.88	-0.88	0.37	0.76	-0.32	-0.74	0.78	0.43	0.4
Property Plant Equipment	0.28	0.37	0.73	0.0	0.28	0.98	0.0	0.56	-0.7	0.92	0.33	0.58	0.25	-0.76	0.6		0.85	-0.23	-0.23	0.19	0.33	-0.01	-0.32	0.24	0.19	0.19
Long Term Debt	-0.19	-0.14	0.3	-0.13	-0.21	0.76	-0.24	0.18	-0.85	0.84	-0.15	0.15	-0.15	-0.98	0.25	0.85		0.15	0.15	-0.23	-0.2	0.21	0.21	-0.19	-0.25	-0.23
Preferred Stock Total Equity	-0.64	-0.84	-0.74	-0.6	-0.69	-0.34	-0.43	-0.33	0.08	-0.4	-0.75	-0.74	-0.8	-0.34	-0.88	-0.23	0.15		1.0	-0.38	-0.82	0.41	0.81	-0.91	-0.46	-0.37
Good Will	-0.64	-0.84	-0.74	-0.6	-0.69	-0.34	-0.43	-0.33	0.08	-0.4	-0.75	-0.74	-0.8	-0.34	-0.88	-0.23	0.15	1.0		-0.38	-0.82	0.41	0.81	-0.91	-0.46	-0.37
Net Tangible Assets	0.94	0.77	0.64	0.45	0.71	0.32	0.69	0.87	0.19	0.02	0.84	0.5	0.53	0.3	0.37	0.19	-0.23	-0.38	-0.38		0.72	-0.67	-0.76	0.66	0.96	0.98
Property Plant And Equipment Net	0.86	0.98	0.86	0.35	0.9	0.47	0.45	0.68	0.15	0.28	0.9	0.85	0.82	0.35	0.76	0.33	-0.2	-0.82	-0.82	0.72		-0.43	-0.99	0.89	0.78	0.72
Net Debt	-0.68	-0.52	-0.41	-0.63	-0.37	-0.17	-1.0	-0.45	-0.06	-0.03	-0.61	-0.3	-0.4	-0.28	-0.32	-0.01	0.21	0.41	0.41	-0.67	-0.43		0.48	-0.5	-0.64	-0.67
Retained Earnings	-0.89	-0.99	-0.87	-0.43	-0.94	-0.46	-0.5	-0.73	-0.11	-0.27	-0.94	-0.84	-0.84	-0.36	-0.74	-0.32	0.21	0.81	0.81	-0.76	-0.99	0.48		-0.92	-0.83	-0.74
Non Current Assets Total	0.82	0.94	0.82	0.72	0.82	0.37	0.52	0.62	-0.07	0.33	0.91	0.77	0.91	0.37	0.78	0.24	-0.19	-0.91	-0.91	0.66	0.89	-0.5	-0.92		0.74	0.61
Non Currrent Assets Other	0.94	0.84	0.7	0.48	0.82	0.34	0.66	0.88	0.15	0.05	0.91	0.64	0.61	0.34	0.43	0.19	-0.25	-0.46	-0.46	0.96	0.78	-0.64	-0.83	0.74		0.94
Cash And Short Term Investments	0.95	0.76	0.63	0.37	0.71	0.33	0.69	0.84	0.26	0.0	0.82	0.52	0.44	0.3	0.4	0.19	-0.23	-0.37	-0.37	0.98	0.72	-0.67	-0.74	0.61	0.94

Click cells to compare fundamentals

SpringWorks Therapeutics Account Relationship Matchups

SpringWorks Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	334.8M	576.2M	452.5M	630.2M	725.8M	762.1M
Other Current Liab	9.3M	14.9M	25.4M	39.2M	65.6M	68.8M
Total Current Liabilities	12.0M	17.6M	30.0M	51.0M	78.2M	82.1M
Total Stockholder Equity	322.1M	557.1M	422.4M	(569.9M)	626.2M	657.5M
Accounts Payable	2.7M	1.4M	3.4M	8.0M	7.4M	7.8M
Cash	327.7M	147.1M	104.0M	67.5M	176.1M	184.9M
Other Assets	1.7M	2.6M	3.3M	3.2M	3.7M	2.2M
Other Current Assets	3.7M	4.9M	9.4M	7.5M	12.7M	13.3M
Total Liab	12.8M	19.1M	30.1M	72.1M	99.6M	104.5M
Property Plant Equipment	795K	3.0M	4.2M	18.3M	16.4M	14.7M
Net Tangible Assets	322.1M	557.1M	422.4M	558.2M	641.9M	336.2M
Property Plant And Equipment Net	795K	3.0M	4.2M	18.3M	24.1M	25.3M
Net Debt	(327.7M)	(144.4M)	(102.7M)	(62.2M)	(169.0M)	(177.4M)
Retained Earnings	(73.0M)	(118.6M)	(292.5M)	(569.9M)	(895.0M)	(850.3M)
Non Current Assets Total	3.5M	62.8M	69.6M	30.5M	224.9M	236.1M
Non Currrent Assets Other	1.7M	2.6M	3.3M	3.2M	4.2M	2.5M
Cash And Short Term Investments	327.7M	508.5M	373.5M	597.0M	479.2M	368.0M
Common Stock Shares Outstanding	43.0M	43.3M	48.5M	53.3M	63.1M	49.5M
Liabilities And Stockholders Equity	334.8M	576.2M	452.5M	(497.9M)	725.8M	762.1M
Non Current Liabilities Total	789K	1.5M	129K	21.0M	21.4M	13.9M
Other Stockholder Equity	395.1M	675.6M	715.2M	761K	1.5B	1.6B
Net Invested Capital	322.1M	557.1M	422.4M	558.2M	626.2M	386.6M
Long Term Investments	976K	57.2M	62.1M	9.0M	185.3M	194.6M
Property Plant And Equipment Gross	795K	1.1M	5.2M	19.5M	26.7M	28.1M
Total Current Assets	331.4M	513.4M	382.9M	599.8M	500.9M	374.9M
Accumulated Other Comprehensive Income	(334.8M)	41K	(312K)	(767K)	1.2M	1.3M
Net Working Capital	319.4M	495.8M	352.9M	548.7M	422.7M	344.6M

Currently Active Assets on Macroaxis

LAAC	Lithium Americas Corp
F	Ford Motor
CHPT	ChargePoint Holdings
AXL	American Axle Manufacturing
ICLN	iShares Global Clean

When determining whether SpringWorks Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of SpringWorks Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Springworks Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Springworks Therapeutics Stock:

How To Invest In SpringWorks

Details

Is SpringWorks Stock a good investment?

Details

What is SpringWorks Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in SpringWorks Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy SpringWorks Stock please use our How to Invest in SpringWorks Therapeutics guide.

You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.

Complementary Tools for SpringWorks Stock analysis

When running SpringWorks Therapeutics' price analysis, check to measure SpringWorks Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SpringWorks Therapeutics is operating at the current time. Most of SpringWorks Therapeutics' value examination focuses on studying past and present price action to predict the probability of SpringWorks Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SpringWorks Therapeutics' price. Additionally, you may evaluate how the addition of SpringWorks Therapeutics to your portfolios can decrease your overall portfolio volatility.

	Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings
	Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios
	Transaction History View history of all your transactions and understand their impact on performance
	Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon
	Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
	Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.

Is SpringWorks Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of SpringWorks Therapeutics. If investors know SpringWorks will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about SpringWorks Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(5.15)

Revenue Per Share

0.086

Return On Assets

(0.32)

Return On Equity

(0.55)

The market value of SpringWorks Therapeutics is measured differently than its book value, which is the value of SpringWorks that is recorded on the company's balance sheet. Investors also form their own opinion of SpringWorks Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is SpringWorks Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because SpringWorks Therapeutics' market value can be influenced by many factors that don't directly affect SpringWorks Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between SpringWorks Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if SpringWorks Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, SpringWorks Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

SpringWorks Net Invested Capital vs Capital Surpluse Analysis

Net Invested Capital vs Capital Surpluse

Net Invested Capital vs Capital Surpluse Correlation Analysis

Correlation Coefficient

Net Invested Capital

Capital Surpluse

SpringWorks Therapeutics fundamental ratios Correlations

SpringWorks Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

SpringWorks Therapeutics fundamental ratios Accounts

Currently Active Assets on Macroaxis

Complementary Tools for SpringWorks Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Good Will	+ 1.0	Preferred Stock Total Equity
Property Plant And Equipment Net	+ 0.98	Other Current Liab
Property Plant Equipment	+ 0.98	Accounts Payable
Cash And Short Term Investments	+ 0.98	Net Tangible Assets
Other Current Assets	+ 0.97	Other Current Liab
Non Currrent Assets Other	+ 0.96	Net Tangible Assets

Net Debt	- 1.0	Cash
Retained Earnings	- 0.99	Property Plant And Equipment Net
Retained Earnings	- 0.99	Other Current Liab
Long Term Debt	- 0.98	Intangible Assets
Retained Earnings	- 0.94	Other Current Assets
Retained Earnings	- 0.94	Other Liab